Gilles Bernard Tremblay,Elisabeth Viau,Mario Filion
申请号：
US14374967
公开号：
US20150044220A1
申请日:
2013.02.22
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in treatment of cancer are thus provided herewith.
